Swiggy adds noon CEO Faraz Khalid to board as SoftBank, Accel step down
Khalid's appointment brings global ecommerce and quick-commerce expertise to Swiggy at a time when the company is scaling its convenience platforms in India. Under his leadership, noon has expanded into food delivery, fintech and quick commerce across the Gulf region. He previously co-founded fashion platform Namshi, which was acquired for $335 million in 2023 by Dubai billionaire Mohamed Alabbar and Saudi Arabia's sovereign fund Public Investment Fund-backed noon.
With this move, Accel Partner Anand Daniel and SoftBank Investment Advisers' Managing Partner and head of EMEA & India Sumer Juneja resigned as non-executive, non-independent directors. Both cited professional commitments and confirmed there were no other material reasons for their resignations. The two have been associated with Swiggy since its early funding rounds and have played key roles in its growth over the past decade.
Swiggy chairperson Anand Kripalu said the refreshed board structure, which now includes four independent directors, reinforces the company's long-term governance priorities. 'We are delighted to welcome Faraz to the Board… and extend our heartfelt thanks to Sumer and Anand for their invaluable contributions,' he said.
Founder and Group CEO Sriharsha Majety described Khalid as a 'visionary leader in ecommerce,' adding that his strategic and operational experience would be crucial as Swiggy enters its next phase of growth.
Separately, Swiggy has reappointed chartered accountant Shailesh Haribhakti for a second term as independent director from January 2026, and named Cauveri Sriram, an industry veteran formerly with the Tata group, as the company's new company secretary and compliance officer.
The governance overhaul comes six days before Swiggy, which operates food delivery and quick commerce services across more than 700 cities while also expanding newer offerings such as Snacc, Pyng and Scenes, is set to report earnings results of the first quarter of the financial year ending March 2026.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
30 minutes ago
- Mint
AI is listening to your meetings. Watch what you say.
Tiffany N. Lewis was worried she was being duped. A potential client had reached out about working with her digital marketing agency on a pro-bono basis, but his message went straight to spam. Then he blew off several scheduled meetings with Lewis. Was he a fraud? When the client asked her to meet again, Lewis added him to a call she was already on with her assistant. Before he joined, Lewis joked: 'Is he, like, a Nigerian prince?" Despite the scammy red flags, he turned out to be a legitimate person. Lewis was relieved—until she realized her new client had received a full summary of the call in his inbox, including her 'Nigerian prince" remark. She was running an AI notetaker the whole time. 'I was very lucky that the person I was working with had a good sense of humor," said Lewis, who lives in Stow, Ohio. AI is listening in on your work meetings—including the parts you don't want anyone to hear. Before attendees file in, or when one colleague asks another to hang back to discuss a separate matter, AI notetakers may pick up on the small talk and private discussions meant for a select audience, then blast direct quotes to everyone in the meeting. Nicole and Tim Delger run a Nashville branding firm called Studio Delger. After one business meeting late last year, the couple received a summary from Zoom's AI assistant that was decidedly not work-related. Zoom AI documented a private conversion between Nicole and Tim Delger, who run a branding firm. 'Studio discussed the possibility of getting sandwich ingredients from Publix," one bullet point said. Another key takeaway: 'Don't like soup." Their client never showed up to the meeting, and the studio had spent the time talking about what to make for lunch. 'That was the first time it had caught a private conversation," Nicole said. Fortunately the summary didn't go to the client. Andrea Serra, an account-strategy coordinator at a communications agency, has experienced this firsthand. In one transcript, an AI notetaker caught her describing her frustration with the new Whole Foods in her neighborhood; though she'd set her preferences so that notes go to the host only, she shared the email with two other people on the call for laughs. Another meeting recap featured bullets of her discussing almost burning down her kitchen trying to make a new sweet potato recipe. 'It'll be like all of our action steps, all the strategy we discussed during the meeting, and then randomly in there, something about our personal lives that we had talked about last week and wanted to catch up on this week as well," Serra said. 'Just one little sentence as a surprise in there." Though her boss, Debora Lima, had hoped the AI summaries would reduce work for the team, she's still waiting for the technology to improve. Meanwhile, she and her colleagues have embraced them as comic relief. As she was looking over notes from a meeting she recently hosted, she noticed the phrase 'hey cutie pie" in the transcript. Lima said there should be a companywide Slack channel to archive the funniest examples. Notetakers can do a variety of tasks from recording and transcribing calls, generating action items for teams and recapping what's already been said to anyone joining late. Many signal to attendees that a meeting is being recorded and transcribed. A demo of what Google's AI notetaker looks like during a meeting. Zoom's AI Companion, which generated more than 7.2 million meeting summaries by the end of January 2024, flashes a dialogue box at the top of the screen to let participants know when it's turned on. As long as it's active, an AI Companion diamond icon continues to flash in the top right hand corner of the meeting. People can also ask the host to stop using the AI companion. 'We want users to feel they're really in control," said Smita Hashim, chief product officer at Zoom. Google's AI notetaker functions similarly, where only meeting hosts or employees of the host organization have the ability to turn it on or off. When it's on, people will see a notification and hear an audio cue, and a blue pencil icon will appear in the top right corner. 'We put a lot of care into making sure meeting participants know exactly if and when AI tools in Meet are being used," said Awaneesh Verma, senior director of product management and real time communications at Google Workspace. The automatic summaries can be informative and timesaving, or unintentionally hilarious. Kelsey Ogletree, chief executive of a tech platform for media professionals, received a Zoom AI summary titled 'Monty's Messy Morning," describing how her dog, Monty, ate leftover food on the counter and threw up in the house. It went on to say that 'Kelsey was disgusted by the incident and considered washing Monty's head with Dawn dish soap." It was a conversation between her and her husband, who's also her business partner. (And Monty is a cat, not a dog.) John Barentine, an astronomer and consultant in Tucson, Ariz., doesn't use AI notetakers but has been on plenty of calls with them. He was most recently surprised by the AI summary of one call that was sent to him, summarizing the small talk at the beginning of the call. It said: 'John Barentine humorously notes that there is a lethal dose of water for humans." Barentine said he was discussing the devastating Texas floods with a client; the AI had completely misunderstood the context. He says he's now more likely to use the private chat feature in meetings instead of saying something aloud while AI is listening. 'At least I know that if I make a remark to somebody privately for now, that's not being swept up by the AI notetaker," he said. Write to Ann-Marie Alcántara at
Time of India
2 hours ago
- Time of India
Trump's threat spells uncertainty for exporters
AP photo New Delhi: American President Donald Trump's latest announcement of a possible "substantial increase" in tariffs on Indian goods, added to the uncertainty for exporters, amid indications that govt was looking at select segments of affected industries instead of a broad-based support. To go ahead with the orders for the upcoming busy season around Christmas, tariff uncertainty is seen as the biggest issue as the buyers would compare the tariffs across countries before finalising them. In several sectors where India is competitive, including textiles and footwear, rival countries such as Bangladesh enjoy a five percentage point tariff advantage. But with the unspecified "penalty" on India for its Russian oil purchases, buyers would be unable to do the arithmetic. Besides, they would be worried about the possibility of the additional tariff coming into force over the next few months when the order is in the pipeline. As a result, they may be deterred from placing orders with Indian suppliers, many of whom they have dealt with over the years. Govt sources said that the exporters need to provide detailed analysis of the segments that will be hit by the 25% tariff. A broad-based comparison may not work as there may be other factors at play. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Learn 57+ Languages Easily with AI [Join] Talkpal AI Undo For instance, when it comes to shrimps, Ecuador is seen to be a major beneficiary of Trump's tweaked tariff announcements. But it may not have the capacity to completely replace Indian exports, estimated at over $2 billion. That's because it's a product segment where production can't be stepped up by running more machines, pointed industry and govt sources. Besides, the exporters would need to meet American standards and get the required certification, which takes time. Similarly, when it comes to textiles, not all segments will be hit equally hard. Besides, Indian players have a strong footing in some of them. For instance, when it comes to cotton T-shirts, India has a 36% share of the women's and girl's dress segment in the US. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
Economic Times
2 hours ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
